Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study

PURPOSE: To investigate the impact of metabolic syndrome (MetS) on pathologic complete response (pCR) and clinical outcomes in breast cancer (BC) patients who received neoadjuvant chemotherapy (NAC). METHODS: We analyzed 221 female BC patients at Harbin Medical University Cancer Hospital who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhaoyue, Zhang, Yue, Li, Yue, Jiang, Cong, Wu, Yang, Shang, Lingmin, Huang, Yuanxi, Cheng, Shaoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845900/
https://www.ncbi.nlm.nih.gov/pubmed/36686748
http://dx.doi.org/10.3389/fonc.2022.1080054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845900/
https://www.ncbi.nlm.nih.gov/pubmed/36686748
http://dx.doi.org/10.3389/fonc.2022.1080054

Ejemplares similares